BioNTech has snagged a small upfront fee to enter into an immuno-oncology co-development pact with Genmab. The deal was unveiled one week after Eli Lilly invested $30 million (€27 million) in BioNTech as part of an immuno-oncology deal worth a potential $300 million per asset.
Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models relevant to multiple sclerosis.
China and Russia have become new targets for compulsory-licensing campaigns as an activist group widens its global challenge to Gilead's expensive Sovaldi (sofosbuvir) hepatitis C drug.
Royal Philips and the Massachusetts Institute of Technology (MIT) have partnered in a 5-year research alliance with a $25 million budget to develop novel product solutions in healthcare and lighting.
The MD Anderson Cancer Center at Cooper has partnered with behavioral health technology player Polaris Health Directions to start a pilot test using the Apple Watch that integrates patient behavioral data into electronic health records and population health data.
Japan's Takeda Pharmaceutical has reached an agreement to distribute Kaketsuken's influenza vaccine domestically in the 2015-2016 season as the government makes a major push to cover the elderly population.
Johnson & Johnson, fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' pipeline of antiviral treatments.
"Cover all the bases" is the theme of FierceDrugDelivery 's annual list of the top drug delivery partnerships. Finding 10 significant alliances that represent the full range of drug delivery advances was a challenge, and there are certainly other deals out there that are both novel and of high importance.
Boehringer Ingelheim has exercised an option to buy PXS4728A from Australia-based Pharmaxis and develop it for the treatment of the liver-related condition NASH with the candidate also showing potential in chronic obstructive pulmonary disease.
J. Craig Venter's Human Longevity (HLI) is joining forces with Cleveland Clinic for a human genomics collaboration aimed at disease discovery, a little more than a year after the company kicked off operations with the promise of building the world's biggest human gene-sequencing platform.